Blog Posts
Grainne O’Kane
Photo taken from Grainne O’Kane/X

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:

“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.

  • Important to remember most on PDAC trials less than 70 years.
  • Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
  •  Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
  • Need to identify who can benefit and discuss with patients.”

GIANT trial

Source: Grainne O’Kane/X

5‐Fluorouracil ASCO ASCO24 cancer Gemcitabine plus nab-Paclitaxel (GnP) Grainne O’Kane OncoDaily Oncology Overall survival (OS) pancreatic ductal adenocarcinoma (PDAC)